Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

It's frustrating to deal with sinus problems, and the pollution just makes everything worse, leaving me feeling helpless and ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Nasal sprays are the quick fix for stuffy noses, the secret weapon against allergy season, and a lifesaver when you need to ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Have you ever been frustrated by one side of your nose feeling completely blocked while the other is clear? As annoying as it ...

Oral phenylephrine was shown to be ineffective for treating nasal congestion over a year go. This week, the FDA took the ...